The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial
{{output}}
Background: Economic evaluations often rely on immature data to evaluate cost-effectiveness of new treatments. Pembrolizumab was approved for advanced non-small cell lung cancer with high PD-L1 expression based on interim data fr... ...
